Marqués de Valdecilla University Hospital (Cantabria)

The Ministry of Health has announced that Spain will receive the MV Hondius in the Canary Islands “in accordance with international law and the spirit of humanitarianism”. The government is thus responding to a request from the World Health Organisation (WHO) and the European Union for the cruise ship, which is travelling from Argentina and has an outbreak of hantavirus on board, to dock in the Canary Islands, in the port of Granadilla, Tenerife. The European Centre for Disease Prevention and Control has assessed which passengers should be evacuated from the ship to Cape Verde, where it is currently located, and which will continue on to the Canary Islands. Once there, they will be examined and transferred to their home countries in accordance with safety protocols. The cruise ship is expected to arrive in the archipelago in three or four days.

Measles cases in Europe and Central Asia fell in 2025 compared with 2024, according to preliminary data reported by 53 countries in the World Health Organization (WHO) European Region. This decline aligns with the preliminary figures published this week by the European Centre for Disease Prevention and Control (ECDC). According to the WHO, countries in Europe and Central Asia reported 33,998 measles cases in 2025, representing a decrease of nearly 75 % compared with the 127,412 cases recorded in 2024. In Spain, however, the number of cases has increased, as shown by data from the Carlos III Health Institute. A few weeks ago, the WHO announced that Spain had lost its measles-free status.

Physical inactivity is a risk factor for the onset of Alzheimer's disease. An international team has studied nearly 300 people with preclinical Alzheimer's—without symptoms but with an accumulation of tau and beta-amyloid proteins in the brain—for 14 years to find out whether physical exercise can also influence its progression. The results indicate that even very moderate activity—walking between 3,000 and 5,000 steps per day—was associated with slower deterioration, while the benefits—which appear to be related to lower tau protein deposits—were greater and tended to stabilise with activity involving between 5,000 and 7,500 steps. The results are published in the journal Nature Medicine.

A US team has analysed the presence of beta-amyloid deposits – which are linked to Alzheimer's disease – in the post-mortem retinas of four people with covid-19 and found that they were larger than in four people without covid. In complementary experiments, the SARS-CoV-2 spike protein in retinal organoids produced an increase in deposits, while the use of a drug that blocks the virus from binding to neurons reduced their accumulation. The results are published in the journal Science Advances.

An international team with Spanish participation has analysed the usefulness of a blood biomarker - the p-tau217 protein - for detecting Alzheimer's disease in 1,767 patients. According to the authors, who publish the results in the journal Nature Medicine, the test has detected the disease with high reliability in four hospital cohorts, as well as in a primary care cohort. They add that it is an assay that can be easily implemented in clinical laboratories and is already routinely used in some centres in Spain.

The DIAN-TU platform is an initiative to test Alzheimer's disease treatments early, by recruiting people with a mutation that leads to developing the disease in the future. One of the trials with the anti-amyloid drug gantenerumab ended without reaching the targets. However, a continuation of the study in 73 patients suggests - for the first time, according to the authors - that long-term, high-dose treatment given some time before symptoms develop could delay the onset of the disease. The results are published in the journal The Lancet Neurology. 

A review of 14 studies and data from more than 130 million patients has found an association between the use of drugs such as anti-inflammatory drugs, antibiotics and vaccines and a reduced risk of dementia. The authors recall that “the fact that a particular drug is associated with an altered risk of dementia does not necessarily mean that it causes or helps against it.” However, “pooling these huge health data sets provides a source of evidence that can help us decide which drugs to try first.” The research is published in the journal Alzheimer's and Dementia: Translational Research & Clinical Interventions. 

A study by Italian researchers has tested a treatment administered as a nasal spray to slow down early-stage Alzheimer's disease. Administered in mice, the treatment inhibits an enzyme linked to the disease and to insulin resistance. According to the researchers, who publish the work in the journal PNAS, application of the spray to the animals “can counteract the accumulation of harmful proteins in neurons and delay the onset and progression of cognitive decline”. 

The European Medicines Agency (EMA) has recommended not granting marketing authorization for Leqembi™ (lecanemab) for the treatment of Alzheimer's disease. The EMA's Committee for Medicinal Products for Human Use (CHMP) considers that its effect in delaying cognitive decline does not outweigh the risk of serious side effects associated with the drug, in particular swelling and possible bleeding in patients' brains. Leqembi™ was approved in 2023 in the United States.

A family of more than 1,000 members with origins in Colombia has a mutation called "paisa" that leads to the development of Alzheimer's disease. In 2019, an added mutation in the apoE gene called "Christchurch" was described as conferring strong protection to an individual carrying two copies of it. Now, a study has found that 27 family members carry a single copy and that it is also associated with some degree of protection. According to the authors, who publish their findings in the journal NEJM, the discovery could be used to develop new treatments for the disease.